Early 18F-FDG uptake as a reliable imaging biomarker of T790M-mediated resistance but not MET amplification in non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors.
about
Early 18F-FDG uptake as a reliable imaging biomarker of T790M-mediated resistance but not MET amplification in non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 October 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Early 18F-FDG uptake as a reli ...... FR tyrosine kinase inhibitors.
@en
Early 18F-FDG uptake as a reli ...... FR tyrosine kinase inhibitors.
@nl
type
label
Early 18F-FDG uptake as a reli ...... FR tyrosine kinase inhibitors.
@en
Early 18F-FDG uptake as a reli ...... FR tyrosine kinase inhibitors.
@nl
prefLabel
Early 18F-FDG uptake as a reli ...... FR tyrosine kinase inhibitors.
@en
Early 18F-FDG uptake as a reli ...... FR tyrosine kinase inhibitors.
@nl
P2093
P2860
P1433
P1476
Early 18F-FDG uptake as a reli ...... FR tyrosine kinase inhibitors.
@en
P2093
Marcello Monti
Rosa Fonti
Silvana Del Vecchio
Viviana De Rosa
P2860
P2888
P356
10.1186/S13550-016-0229-0
P577
2016-10-10T00:00:00Z
P6179
1036527111